Who are Cyclobenzaprine hydrochloride 2%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): cyclobenzaprine ER (AMRIX).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyclobenzaprine-hydrochloride-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Cyclobenzaprine hydrochloride 2% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cyclobenzaprine hydrochloride 2% (Cyclobenzaprine hydrochloride 2%) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscle relaxant (centrally acting). Area: Musculoskeletal/Pain Management.

phase 2 Muscle relaxant (centrally acting) Musculoskeletal/Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Cyclobenzaprine hydrochloride 2% (Cyclobenzaprine hydrochloride 2%) — Express Specialty Pharmacy. Cyclobenzaprine is a centrally acting muscle relaxant that reduces muscle tension by depressing activity in the brainstem.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyclobenzaprine hydrochloride 2% TARGET	Cyclobenzaprine hydrochloride 2%	Express Specialty Pharmacy	phase 2	Muscle relaxant (centrally acting)
cyclobenzaprine ER (AMRIX)	cyclobenzaprine ER (AMRIX)	State University of New York - Upstate Medical University	marketed	Muscle relaxant (centrally acting)	Brainstem monoamine receptors (non-selective); structurally related to tricyclic antidepressants

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscle relaxant (centrally acting) class)

Express Specialty Pharmacy · 1 drug in this class
State University of New York - Upstate Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyclobenzaprine hydrochloride 2% — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclobenzaprine-hydrochloride-2. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab